SCHEMBL3089402

SCHEMBL3089402

CC(C)(C)OC(=O)NCCC(=O)Nc1ccon1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.50
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
HDAC3 O15379 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
CASP1 P29466 1/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
GAPDH P04406 1/20 0.43
KDM4E B2RXH2 6/20 0.43
POLB P06746 1/20 0.43
CYP3A4 P08684 1/20 0.42
ALDH1A1 P00352 2/20 0.41
RXFP1 Q9HBX9 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALPL P05186 1/20 0.41
ALPI P09923 1/20 0.41
ALPG P10696 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL445249 0.82 RAB9A (0.49) ATML3MBTL1KDM4EPOLBALDH1A1
SCHEMBL3094315 0.81 ALDH1A1 (0.57) HTTPOLBALDH1A1GAAMAPT
SCHEMBL8692897 0.78 CA1 (0.66) CA1CA2HDAC3HDAC1HDAC2
SCHEMBL3146288 0.77 GAA (0.54) HDAC3HDAC1HDAC2HDAC8HTT
SCHEMBL10078096 0.75 CA1 (0.47) CA1CA2L3MBTL1KDM4EPOLB
SCHEMBL13936405 0.75 CA1 (0.49) CA1CA2L3MBTL1KDM4EPOLB
SCHEMBL6274441 0.74 CA1 (0.58) CA1CA2HDAC3HDAC1HDAC2
SCHEMBL6104799 0.74 CA12 (0.50) CA1CA2HTTL3MBTL1CYP3A4
SCHEMBL30722391 0.73 KDM4E (0.42) CA1CA2HDAC3HDAC1HDAC2
SCHEMBL14679151 0.73 CA1 (0.60) CA1CA2HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7799810-B2 Organic compounds NOVARTIS AG (CH) 2010-09-21 US disclosed
US-20100120865-A1 Organic compounds NOVARTIS AG (CH) 2010-05-13 US disclosed
EP-2035413-A2 THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS Novartis AG (CH) 2009-03-18 EP disclosed
WO-2008000421-A2 THIAZOLYL UREA DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120865-A1 Organic compounds PIK3C3, PIK3R3, PIK3R4 ATM 1498/4885CA1 1783/4885CA2 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.